Recent Articles in Deals & Financings

Shanghai DualityBio plans to conduct a Hong Kong IPO to support its portfolio of ADC therapeutics for cancer and autoimmune diseases. Founded in 2019, DualityBio has built an innovative and differentiated pipeline of 12 ADC candidates, discovered in-house. These include six clinical-stage ADCs aimed at indications with unmet medical needs, two next-generation bispecific ADCs (BsADCs) and one autoimmune ADC planned for clinical trials over the next two years. The company has forged partnerships with BioNTech SE, BeiGene, Ltd. and Adcendo ApS with a total deal value of more than $4.0 billion. More details....

Share this with colleagues:  

Hangzhou’s Huadong Pharmaceutical acquired rights for two immune disease therapies from IMBiologics of South Korea in a $383 million agreement plus royalties. $8 million of the total are upfront payments. The two candidates are both antibodies: IMB-101 is a bispecific that targets both the autoimmune disease antibody OX40L and tumor necrosis factor (TNF); IMB-102 is a monospecific antibody IMB-102 that targets OX40L. Earlier this year, IMBiologics sold US rights to the pair in a $995 million deal with Navigator Medicines. More details....

Share this with colleagues:  

India’s Dr. Reddy’s Laboratories, together with its CRDMO Aurigene Pharmaceutical, signed a non-binding MOU with Kainomyx, a US company, to develop an affordable anti-malaria drug. Kainomyx discovers small molecule therapeutics for neglected tropical diseases, with a focus on malaria. It targets cytoskeletal proteins of parasites to advance drug development and offers tests to identify asymptomatic carriers. According to the companies, the MOU combines Kainomyx’s novel drug discovery expertise, Aurigene’s experience with integrated drug discovery and development, and Dr. Reddy’s commercialization ability, especially in low and middle-income countries. More details....

Share this with colleagues:  

Shanghai Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor (TF) ADC to Denmark’s Adcendo in a $1 billion agreement. The candidate, ADCE-T02, is a highly differentiated anti-TF ADC with a Topoisomerase I inhibitor-based linker/payload, according to Multitude. The $1 billion value of the agreement includes upfront and milestone payments, with potential royalties on sales also available. Multitude is starting a Phase I trial of the candidate in Australia, with additional trials planned for the US and EU. More details....

Share this with colleagues:  

EA Pharma sold global rights for a small molecule calcimimetic that may control intact parathyroid hormone levels in patients with secondary hyperparathyroidism receiving hemodialysis. Upacicalcet is an intravenous therapy. EA Pharma, a subsidiary of Eisai Pharma of Japan, sold the rights to North Carolina’s Pathalys Pharma, a biopharma that develops best-in-class therapies for chronic kidney diseases. At the same time, Pathalys received an initial seed financing from DaVita Venture Group, and Catalys Pacific. Catalys Pacific is a Tokyo-San Francisco investor. More details....

Share this with colleagues: